TTNP (Titan Pharmaceuticals) ROCE %: -112.67% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTNP Titan Pharmaceuticals Inc TTNP
9 GF Score
Price $4.61
View Full Analysis

What is Titan Pharmaceuticals ROCE %?

Titan Pharmaceuticals TTNP 9 ROCE % is -112.67% as of Jun. 2025. GuruFocus rates TTNP with a GF Score™ of 9/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Titan Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2025 was -112.67%.

Titan Pharmaceuticals  (NAS:TTNP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Titan Pharmaceuticals ROCE % Related Terms

Titan Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Titan Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals ROCE % Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -150.24 -203.59 -303.12 -180.35 -100.35

Titan Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.59 -83.49 -93.95 -98.96 -112.67
TTNP
9GF Score
Titan Pharmaceuticals Inc TTNP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Pharmaceuticals ROCE % Calculation

Titan Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-4.557/( ( (8.086 - 1.444) + (2.923 - 0.483) )/ 2 )
=-4.557/( (6.642+2.44)/ 2 )
=-4.557/4.541
=-100.35 %

Titan Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Mar. 2025 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Mar. 2025 )(Q: Jun. 2025 )
=-2.628/( ( (2.156 - 0.279) + (3.051 - 0.263) )/ 2 )
=-2.628/( ( 1.877 + 2.788 )/ 2 )
=-2.628/2.3325
=-112.67 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -112.67% mean?
Titan Pharmaceuticals (TTNP) has a ROCE % of -112.67% as of Jun. 2025.
Is Titan Pharmaceuticals' ROCE % too high?
Titan Pharmaceuticals' current ROCE % is -112.67%. Overall, Titan Pharmaceuticals has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Titan Pharmaceuticals' ROCE % compare to TCRT and SXTP?
Titan Pharmaceuticals' ROCE % of -112.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Titan Pharmaceuticals's current ROCE % is -112.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Pharmaceuticals stock overvalued right now?
Titan Pharmaceuticals (TTNP) has a current ROCE % of -112.67%. The current ROCE % is -112.67%. Titan Pharmaceuticals' overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Titan Pharmaceuticals (TTNP), the current ROCE % is -112.67% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Titan Pharmaceuticals Business Description

Address 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
9GF Score

Get the complete analysis for TTNP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price